Comparative Risk of Oral Complications Associated with Medications for Opioid Use Disorder: A Mixed-Methods Approach
Comparative Risk of Oral Complications Associated with Medications for Opioid Use Disorder: A Mixed-Methods Approach
批准号:
10765049
负责人:
Anne Mobley Butler
金额:
$127.51万
依托单位国家:
美国
项目类别:
财政年份:
2023
资助国家:
美国
项目状态:
未结题
起止时间:
2023-09-21 至 2025-09-20
关键词:
AccountingAddressAdherenceAdverse eventAttitudeBenefits and RisksBuprenorphineCase SeriesCase StudyCessation of lifeCharacteristicsClinicalCommunicationDataData SetDatabasesDecision MakingDentalEdentulous MouthEducationEnsureEpidemiologic MethodsEtiologyEvaluationFormulationFosteringGoalsHealthHealth Services ResearchHealthcareHelping to End Addiction Long-termHourIndividualInjectableInterventionInterviewKnowledgeLifeLinkMedicaidMedicalMedicineMethadoneMethodologyMethodsModernizationMorbidity - disease rateMucous MembraneNaltrexoneObservational StudyOralOral healthOutcomeOverdosePainPatientsPersonsPharmaceutical PreparationsPopulationProcessProviderQualitative MethodsRadarRecommendationReportingRiskSafetySalivarySamplingSelection BiasStructureSystemTestingTooth ExtractionTooth structureTractionUnited States Food and Drug AdministrationUnited States National Institutes of HealthWritingXerostomiaactive comparatoraddictioncase findingclinical practicecomparativecomparative safetydesignempowermentequilibration disorderexperiencehealth care service utilizationhuman centered designillicit opioidinnovationlong term abstinencemedication for opioid use disordermedication safetymicrobialmortalityopioid epidemicopioid useopioid use disorderoral careoral infectionpilot testprototyperisk mitigationsafety studysocial stigmasugartreatment choiceuptakeusability
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Project Summary/Abstract
Combating the opioid epidemic is a federal priority. While medications for opioid use
disorder (MOUD) substantially reduce mortality, treatment uptake remains low due to
multiple barriers, including societal stigma as well as patient and provider safety
concerns. In January 2022, the US Food and Drug Administration (FDA) released a
Drug Safety Communication warning that transmucosal buprenorphine for opioid use
disorder (OUD) and pain may be associated with dental problems. This Communication
was based on case reports and adverse events reporting. In the absence of rigorous
evidence, several addiction medicine organizations jointly wrote to the FDA
recommending retraction of the Communication due to overwhelming benefit of
buprenorphine and “flawed analysis regarding causation.” As a result, the FDA
Communication may contribute to barriers for MOUD initiation without rigorous data that
demonstrates a causal effect of MOUD on oral complications. Evaluation of the dental
safety of MOUD is urgently needed to inform clinical practice and support or refute
concerning findings from case series, adverse event reports, and experience of people
with opioid use disorder (PWOUD). The lack of understanding of the effects of MOUD
on oral complications is a critical information gap, as patients and providers need
rigorous evidence to make informed treatment choices and take steps to mitigate risk of
poor dental health. We will conduct an observational study using national databases,
including linked dental and medical claims data for more than 120,000 Medicaid- or
commercially-insured new users of MOUD to treat OUD. Next, we will use qualitative
methods to examine the perspectives of PWOUD on the oral health impact of MOUD,
the FDA Communication, and barriers to obtaining oral health care. Lastly, we will
develop an educational aid using human-centered design activities to inform
discussions of the risks and benefits associated with MOUD and oral complications.
This large study will generate evidence to address critical gaps in knowledge about the
impact of MOUD on adverse oral health outcomes and leverage human-centered
design to create an educational aid for patients. Our results will empower PWOUD to
seek effective dental treatment and foster high-quality, risk-benefit discussions around
MOUD that removes barriers to receiving their life-saving treatment.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Comparative Effectiveness and Safety of Adjuvanted and Other Influenza Vaccine Technologies Among Patients Receiving Dialysis
-
批准号:10726047
-
项目类别:
-
资助金额:$19.53万
-
财政年份:2023
-
负责人:Anne Mobley Butler
-
依托单位:
Identifying Optimal Antibiotic Regimens to Treat Urinary Tract Infections During Pregnancy
-
批准号:10522361
-
项目类别:
-
资助金额:$71.89万
-
财政年份:2022
-
负责人:Anne Mobley Butler
-
依托单位:
Identifying Optimal Antibiotic Regimens to Treat Urinary Tract Infections During Pregnancy
-
批准号:10838231
-
项目类别:
-
资助金额:$5.88万
-
财政年份:2022
-
负责人:Anne Mobley Butler
-
依托单位:
Identifying Optimal Antibiotic Regimens to Treat Urinary Tract Infections During Pregnancy
-
批准号:10672395
-
项目类别:
-
资助金额:$67.31万
-
财政年份:2022
-
负责人:Anne Mobley Butler
-
依托单位:
海外基金